Get the Stockscreener App
75.97
2.16%
-1.68
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $75.97, with a volume of 14.57M.
It is down -2.16% in the last 24 hours and down -7.25% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
See More
Previous Close:
$77.65
Open:
$77.96
24h Volume:
14.57M
Relative Volume:
0.90
Market Cap:
$208.87B
Revenue:
$63.92B
Net Income/Loss:
$17.43B
P/E Ratio:
11.06
EPS:
6.87
Net Cash Flow:
$17.04B
1W Performance:
-8.67%
1M Performance:
-7.25%
6M Performance:
-26.19%
1Y Performance:
-41.66%
1-Day Range:
$75.82
$78.45
1-Week Range:
$75.82
$83.58
52-Week Range:
$75.82
$134.63
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
75.97 | 208.87B | 63.92B | 17.43B | 17.04B | 6.87 |
|
LLY
Lilly Eli Co
|
734.57 | 739.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.22 | 375.64B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
184.60 | 351.09B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
65.77 | 307.32B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
108.70 | 225.73B | 53.22B | 12.86B | 14.85B | 6.39 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Is Merck & Co., Inc. (MRK) the Best Income Stock to Invest in Now? - Insider Monkey
Merck Animal Health To Invest $895M To Expand Production, R&D In Kansas - Business Facilities Magazine
Merck launches $895M Kansas factory expansion amid push to increase domestic production - Crain's New York Business
Merck Animal Health will spend $895M on 200-job expansion in De Soto - The Business Journals
Merck boosts U.S. investments with $895M expansion in Kansas site - MSN
Merck (MRK) to Invest $895M in Kansas Facility Expansion - GuruFocus
Merck’s New Keytruda Shot Is a Rare Real-Time ‘Product Hop’ (1) - Bloomberg Law News
Merck announces $895M expansion in Kansas site (MRK:NYSE) - Seeking Alpha
2 Beaten-Down Stocks That Are Great Buys on the Dip - The Motley Fool
Merck Animal Health announces $895M expansion, new jobs in De Soto - FOX4KC.com
Merck (MRK) Plans Major Expansion of Animal Health Facility in Kansas | MRK Stock News - GuruFocus
Merck Animal Health announces $895 million investment in Kansas - Reuters
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto - Business Wire
Merck & Co., Inc. (MRK): A Bull Case Theory - MSN
Is Merck & Co., Inc. (MRK) the Best Dow Stock? - MSN
Merck (NYSE:MRK) Launches Next-Gen Digital Ecosystem for Growth Disorders with Dawn Health - Yahoo Finance
Merck & Co., Inc. (MRK): Among Billionaire Mario Gabelli’s Large-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Merck to Participate in the Bank of America 2025 Global Healthcare Conference - Business Wire
Multiple System Atrophy (MSA) Market Research 2025-2035 - GlobeNewswire Inc.
Dawn Health and Merck Launch Next-Generation Digital Ecosystem for Growth Disorders - marketscreener.com
FDA Plans to Increase Surprise Inspections at Overseas Manufacturing Sites - marketscreener.com
Are Wall Street Analysts Bullish on Merck Stock? - Nasdaq
Long-Term Investors in shares of Merck & Co., Inc. (NYSE: MRK) - openPR.com
Merck & Co Unusual Options Activity - Nasdaq
Is Merck & Co., Inc. (MRK) The Most Profitable Cheap Stock to Buy Now? - Yahoo Finance
Are Wall Street Analysts Bullish On Merck Stock? - Barchart.com
FDA Action Alert: GSK, Sanofi, Merck and More - BioSpace
Merck invests $1B in Wilmington facility to boost U.S. drug production amid tariff concerns - Audacy
Merck Expands Biomanufacturing with Staggering Investment in Wilmington - VISTA.Today
Merck & Co., Inc. SEC 10-Q Report - TradingView
Merck Stock Price | MRK Stock Quote, News, and History - markets.businessinsider.com
Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology - insights.citeline.com
Merck & Co., Inc. (MRK): Jim Cramer Agrees – “Merck’s A Good Company” - Insider Monkey
Merck & Co. Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Yahoo Finance
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda - BioPharma Dive
June 13th Options Now Available For Merck (MRK) - Nasdaq
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know - Yahoo Finance
AmacaThera and Merck Animal Health Announce Collaboration in Animal Health - Newswire.ca
Pharmaceutical company Merck to invest $1 billion in Delaware plant - The American Bazaar
Is Merck & Co. Inc. (MRK) the Best Dow Stock for the Next 12 Months? - Yahoo Finance
In Brief: Merck To Invest $1bn In New US Biologics Production - insights.citeline.com
Merck & Co courts Washington with Delaware build statement - The Pharma Letter
Merck Shareholder Drops Suit Against Execs Over Gardasil Demand - Bloomberg Law News
Merck & Co., Inc. (MRK): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential - Insider Monkey
Guggenheim Adjusts Merck & Co.'s Price Target to $108 From $115 - marketscreener.com
Guggenheim cuts Merck stock target to $108, keeps Buy rating By Investing.com - Investing.com India
Merck (MRK) Price Target Reduced by Guggenheim Analyst | MRK Sto - GuruFocus
Merck & Co. (MRK) Looks to New Cholesterol Drug as Keytruda Expiration Looms - TipRanks
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):